AK
Aktis Oncology, Inc.
AKTS · NASDAQ
$24.06 -5.91% (-$1.51)
1M -2.87%
Market Cap $1.28B
P/E Ratio -
Div. Yield -
ROE 35.78%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 197.77x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 980.93%
Op. margin 1,149.52%
Quality
0 /100
Poor ROIC 31.79%
ROE 35.78%
ROA 24.06%
Debt
100 /100
Low Current ratio 7.37x
Debt/Equity N/A
Int. coverage N/A
Stability
47 /100
Moderate Beta 0.45x
EPS volatility 36.42%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na AKTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Roden
Employees
79
Headquarters
Boston
Nadcházející události
12 LIS
Earnings
Upcoming earnings report